The microbiome:
an exciting new modality

Finch has a portfolio of innovative microbiome assets

Finch, an early pioneer in the microbiome field, has established a portfolio of innovative microbiome assets with potential applicability to a wide range of product strategies and therapeutic areas. In January 2023, Finch announced a decision to discontinue its Phase 3 trial of CP101 in recurrent C. difficile and focus on realizing the value of its IP estate and other assets.

Our portfolio

Finch has established a leading portfolio of microbiome assets designed with insights from human microbiota transplantation studies.

Learn more

IP estate

Finch has a robust intellectual property estate reflecting the Company’s pioneering role in the microbiome therapeutics field.

Learn more

Recent news

Finch Announces Reverse Stock Split of Common Stock

June 09, 2023

Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates

May 10, 2023

Finch Therapeutics Announces Executive Leadership Transitions

April 25, 2023

Contact us

Interested in exploring a partnership or learning more about our portfolio? Email [email protected] to explore opportunities.